Pamela Vezzoli

Bergamo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

Journal: The British journal of dermatology

Published: May 16, 2026

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Journal: Acta dermato-venereologica

Published: January 09, 2026

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Journal: Acta dermato-venereologica

Published: January 09, 2026

IgA pemphigus following SARS-Cov-2 vaccine.

IgA pemphigus following SARS-Cov-2 vaccine.

Journal: Italian journal of dermatology and venereology

Published: April 18, 2025

A 14-year multicentric follow-up study of atypical pemphigus variants in Italy: the VARIANT_P study.

A 14-year multicentric follow-up study of atypical pemphigus variants in Italy: the VARIANT_P study.

Journal: Clinical and experimental dermatology

Published: April 14, 2025

Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study.

Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study.

Journal: The Journal of dermatology

Published: January 24, 2025

Clinical outcomes of chlormethine gel in mycosis fungoides affecting "sensitive" areas: A retrospective case series.

Clinical outcomes of chlormethine gel in mycosis fungoides affecting "sensitive" areas: A retrospective case series.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: August 09, 2024

Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences.

Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences.

Journal: Drugs in context

Published: June 07, 2024

Metronidazole-induced linear immunoglobulin A disease in a patient suffering from ulcerative colitis: a case report and focused review of the literature.

Metronidazole-induced linear immunoglobulin A disease in a patient suffering from ulcerative colitis: a case report and focused review of the literature.

Journal: Dermatology reports

Published: August 21, 2023

Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.

Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.

Journal: Frontiers in medicine

Published: April 19, 2023

Safety of anti-IL-23 risankizumab treatment in a patient with severe psoriasis and Charcot-Marie-Tooth disease.

Safety of anti-IL-23 risankizumab treatment in a patient with severe psoriasis and Charcot-Marie-Tooth disease.

Journal: The Australasian journal of dermatology

Published: April 16, 2023

Clinical-epidemiological aspects of the Monkeypox 2022 epidemic: A multicentre study by the Italian SIDeMaST Group of Sexually Transmitted, Infectious and Tropical Diseases.

Clinical-epidemiological aspects of the Monkeypox 2022 epidemic: A multicentre study by the Italian SIDeMaST Group of Sexually Transmitted, Infectious and Tropical Diseases.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: February 20, 2023

Showing 1-12 of 30

Last Updated: 09/26/2026